Advanced urothelial carcinoma with fibroblast growth factor receptor 3 (FGFR3) genetic alteration

Advanced urothelial carcinoma with fibroblast growth factor receptor 3 (FGFR3) genetic alteration is a malignancy originating in the transitional epithelium of the urinary tract—most commonly the bladder, ureters, or renal pelvis—that has spread locally into surrounding structures or metastasized to regional lymph nodes and distant organs Clinically, this biomarker-defined entity characterizes an aggressive tumor subset that can be identified via companion genomic profiling to guide molecularly ...

Advanced urothelial carcinoma with fibroblast growth factor receptor 3 (FGFR3) genetic alteration is a malignancy originating in the transitional epithelium of the urinary tract—most commonly the bladder, ureters, or renal pelvis—that has spread locally into surrounding structures or metastasized to regional lymph nodes and distant organs These molecular aberrations produce constitutive, ligand-independent activation of receptor tyrosine kinase signaling via the MAPK and PI3K/AKT pathways, promo...

Advanced urothelial carcinoma with fibroblast growth factor receptor 3 (FGFR3) genetic alteration is a malignancy originating in the transitional epithelium of the urinary tract—most commonly the bladder, ureters, or renal pelvis—that has spread locally into surrounding structures or metastasized to regional lymph nodes and distant organs

It affects adult populations and is biologically defined by susceptible genomic alterations in the *FGFR3* gene, including activating point mutations (such as R248C, S249C, G370C, or Y373C) or oncogenic gene fusions

It affects adult populations and is biologically defined by susceptible genomic alterations in the *FGFR3* gene, including activating point mutations (such as R248C, S249C, G370C, or Y373C) or oncogenic gene fusions These molecular aberrations produce constitutive, ligand-independent activation of receptor tyrosine kinase signaling via the MAPK and PI3K/AKT pathways, promoting dysregulated cellular proliferation, survival, and neoangiogenesis

Clinically, this biomarker-defined entity characterizes an aggressive tumor subset that can be identified via companion genomic profiling to guide molecularly targeted therapy